Note 13 - Subsequent Events (Details Textual) - Subsequent Event [Member] - License Agreement for Late-stage Rare Disease Product Candidate ASN-001 [Member] - Auson Pharmaceuticals [Member]	Jul. 31, 2026 USD ($)
Agreement, Upfront License Fee	$ 3,000
Agreement, Upfront License Fee Period (Day)	30 days
First Commercial Sale After FDA Approval [Member]
Agreement, Milestone Payment	$ 5,000
Sales Milestone One [Member]
Agreement, Milestone Payment	1,000
Agreement, Milestone Payment, Minimum Product Sales	$ 20,000
Agreement, Royalty Rate	10.00%
Agreement, Royalty Rate, Net Product Sales	$ 200,000
Sales Milestone Two [Member]
Agreement, Milestone Payment	2,500
Agreement, Milestone Payment, Minimum Product Sales	$ 40,000
Agreement, Royalty Rate	13.00%
Sales Milestone Two [Member] \| Minimum [Member]
Agreement, Royalty Rate, Net Product Sales	$ 200,000
Sales Milestone Two [Member] \| Maximum [Member]
Agreement, Royalty Rate, Net Product Sales	400,000
Sales Milestone Three [Member]
Agreement, Milestone Payment	5,000
Agreement, Milestone Payment, Minimum Product Sales	$ 80,000
Agreement, Royalty Rate	15.00%
Agreement, Royalty Rate, Net Product Sales	$ 400,000
Sales Milestone Four [Member]
Agreement, Milestone Payment	10,000
Agreement, Milestone Payment, Minimum Product Sales	150,000
Sales Milestone Five [Member]
Agreement, Milestone Payment	10,000
Agreement, Milestone Payment, Minimum Product Sales	$ 280,000